Pharmacokinetics of acyclovir in the cat.

J Vet Pharmacol Ther

Pfizer Inc., Central Research Division, Groton, CT 06340, USA.

Published: December 1996

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2885.1996.tb00087.xDOI Listing

Publication Analysis

Top Keywords

pharmacokinetics acyclovir
4
acyclovir cat
4
pharmacokinetics
1
cat
1

Similar Publications

Background: In cases of maternal primary infection with cytomegalovirus (CMV-MPI) maternal treatment with oral valaciclovir 8 g/day has been shown to reduce the risk of fetal infection. The pharmacological profile of this high dosage during pregnancy is not yet known.

Objectives: To quantify maternal-fetal exposure to valaciclovir 8 g/day in a population pharmacokinetic (popPK) study.

View Article and Find Full Text PDF

This study aimed to develop patches containing quercetin-loaded microcapsules and to evaluate their in vitro and in vivo safety and efficacy in preclinical surveys. A set of in vitro experiments evidenced the virucidal activity of quercetin against the HSV-1-KOS (sensitive to acyclovir) and HSV-1-AR (resistant to acyclovir) strains, with improved outcomes upon the first. The patches presented a homogeneous aspect, were easily handled, had a suitable bioadhesion, and possessed mechanical properties of soft and weak material, besides a pH compatible with human skin.

View Article and Find Full Text PDF

Acyclovir (ACV) is a potentially effective antiviral medication; however, it has a serious drawback, which is its poor solubility, bioavailability, and short half-life. The goal of this study is to improve its drawbacks through the synthesis of nanogels. In this study, the cross-linked hyaluronic acid-grafted poly(acrylamide--itaconic acid) nanogel is synthesized successfully through free radical polymerization and used as a safe pH-responsive carrier for ACV.

View Article and Find Full Text PDF

Background: Despite established antiviral therapy for herpes simplex virus, varicella zoster and cytomegalovirus encephalitis, the outcome remains poor.

Objectives: To assess pharmacokinetic (PK) and pharmacodynamic (PD) data of antiviral drugs in the central nervous system (CNS) to optimize the treatment of Herpesviridae encephalitis.

Sources: PUBMED search 1950 to September 2024, terms (1) "encephalitis" and ("HSV" or "VZV" or "CMV") or (2) cerebrospinal and ("(val)acyclovir" or "(val)ganciclovir" or "foscarnet" or "cidofovir").

View Article and Find Full Text PDF

In vivo systemic evaluation of nasal drug absorption from powder formulations in rats.

Eur J Pharm Biopharm

February 2025

Laboratory of Pharmaceutical Technology, Kobe Pharmaceutical University, 4-19-1 Motoyamakitamachi, Higashinada-ku, Kobe, Hyogo 658-8558, Japan.

Despite the potential benefits of nasal drug delivery, there is a need for a systematic evaluation of the efficacy of powder formulations adhering to the nasal mucosa. This study aims to establish a systematic evaluation method for nasal drug absorption from powder formulations. We selected three model compounds-antipyrine, griseofulvin, and acyclovir-and analyzed their pharmacokinetics following nasal administration of powder formulations under physiological conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!